ProTECT trial to study biomarkers in TBI patients

The US National Institutes of Health (NIH) has awarded a five-year, $2.2m grant to researchers to study biomarkers in the blood of traumatic brain injury (TBI) patients. The research team includes Emory School of Medicine, Banyan Biomarkers, the Medical University of South Carolina, the University of Pittsburgh and the University of Michigan, and it will study patients enrolled in the experimental clinical treatment (ProTECT) III trial, which is assessing the efficacy of progesterone in the treatment of TBI. The multi-site NIH-sponsored clinical study enrolled 1,140 TBI patients across 17 centres nationwide. Banyan Biomarkers Business Development and Analytical Service Department director Andreas Jeromin said the biomarkers will have the potential to improve the ability to diagnose a traumatic brain injury and improve clinical outcomes for patients.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video